Stryker Corporation

Stryker Corporation

SYK

$339.65

Updated: 05/11/2026, 10:08:39

Market Cap
$129.30B
Sector
Healthcare
Industry
Medical - Devices
Country
US

No historical data available

Company Profile

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

USD
NYSE
CEO: Kevin A. Lobo
Employees: 56,000
https://www.stryker.com
Asset Summaries
Latest generated summaries for SYK

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
SYK-10-k-fy2025.html6.2 MBtext/htmlENFiled 11/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 45 KPI observations

Revenue

N/A

FY — · Reported

Net income

$3.2B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$4.3B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

N/A

FY — · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

MedSurg and Neurotechnology product families described
Mako SmartRobotics installed base and expansion

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Global medtech leader

Global medical technology leader; products sold in ~61 countries; impacts >150 million patients annually

98%
Source evidence
“Our products are sold in approximately 61 countries through company-owned subsidiaries and branches as well as third-party dealers and distributors”

Orthopaedics segment product lines

Orthopaedics segment comprises Knees, Hips, Trauma and Extremities, Spinal Implants and Other

95%
Source evidence
“Orthopaedics: Knees $2,656 $2,447 $2,273”

Reliance on indirect distribution channels

Many markets served via indirect distribution channels and independent major distributors, creating risk if channels become insolvent or sell competitive products

94%
Source evidence
“In many markets we rely on indirect distribution channels to market, distribute and sell our products.”

MedSurg and Neurotechnology product families described

Five product lines: Instruments, Endoscopy, Medical (incl. AI-assisted virtual care), Vascular (stroke/VTE), Neuro Cranial (brain/skull, bone grafts, vertebral augmentation)

98%
Source evidence
“MedSurg and Neurotechnology products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments)”

Mako SmartRobotics installed base and expansion

Mako SmartRobotics available in >45 countries; >1M Mako Total Knee and >2M total robotic procedures performed; Mako 4 platform introduced in 2025

95%
Source evidence
“we continued to expand the global footprint of Mako SmartRobotics, which is now available in more than 45 countries. To date, over one million robotic Mako Total Knee procedures and more than two million robotic procedures across Mako Total Knee, Mako Total Hip, and Mako Partial Knee have been performed”

United States vs international net sales, 2025/2024/2023

US net sales $19,006M; International net sales $6,110M in 2025 (US $16,943M / Intl $5,652M in 2024)

99%
Source evidence
“Total $19,006 $16,943 $15,257”

Geographic net sales 2023-2025

US: $19,006M (2025) vs $16,943M (2024); International: $6,110M vs $5,652M; US grew 12.2%, International 8.1% as reported

97%
Source evidence
“United States $19,006 $16,943 $15,257 12.2% 12.2% 11.0% 11.0% International 6,110 5,652 5,241 8.1 6.4”

US vs international split by segment, 2025

2025: MedSurg US $12,305M / Intl $3,342M; Orthopaedics US $6,701M / Intl $2,768M

97%
Source evidence
“$12,305 $10,517 $9,328”

Orthopaedics product-line net sales detail, 2025/2024/2023

Knees $2,656M, Hips $1,865M, Trauma and Extremities $3,948M, Spinal Implants $185M, Other $815M (2025)

99%
Source evidence
“Knees $2,656 $2,447 $2,273”

Total net sales by segment, 2025/2024/2023

MedSurg and Neurotechnology $15,647M; Orthopaedics $9,469M; Total $25,116M (2025), vs $22,595M (2024) and $20,498M (2023)

99%
Source evidence
“$15,647 $13,518 $12,163”

MedSurg and Neurotechnology product-line net sales detail, 2025/2024/2023

Instruments $3,183M, Endoscopy $3,807M, Medical $4,204M, Vascular $1,968M, Neuro Cranial $2,485M (2025)

99%
Source evidence
“Instruments $3,183 $2,834 $2,534 Endoscopy”

Net sales by reportable segment 2023-2025

MedSurg & Neurotech: $15,647M (62%, 2025); Orthopaedics: $9,469M (38%, 2025); Total 2025 $25,116M vs $22,595M (2024) vs $20,498M (2023)

98%
Source evidence
“MedSurg and Neurotechnology $15,647 62% $13,518 60% $12,163 59% Orthopaedics 9,469 38 9,077 40 8,335 41”

MedSurg and Neurotechnology composition 2025

Instruments $3,183M; Endoscopy $3,807M; Medical $4,204M; Vascular $1,968M; Neuro Cranial $2,485M (2025)

97%
Source evidence
“Instruments $3,183 20% $2,834 21% $2,534 21% Endoscopy 3,807 24 3,389 25 3,068 25”

Orthopaedics composition 2025

Knees $2,656M; Hips $1,865M; Trauma and Extremities $3,948M; Spinal Implants $185M (down from $707M); Other $815M (2025)

97%
Source evidence
“Knees $2,656 28% $2,447 27% $2,273 27% Hips 1,865 20 1,704 19 1,544 18”

Operations and dependencies

Approximately 24% of net sales denominated in foreign currencies

~24% of net sales denominated in foreign currencies (AUD, GBP, CAD, EUR, JPY); hedging may not be successful

97%
Source evidence
“approximately 24% of our net sales are denominated in foreign currencies, including the Australian Dollar, British Pound, Canadian Dollar, Euro and Japanese Yen.”

Sole-source supplier reliance

Sole-source procurement of certain raw materials, components, finished devices and services (incl. sterilization services); past electronic component shortage caused limited product availability and lost sales

97%
Source evidence
“several raw materials, components, finished devices and services are procured from a sole source due to, among other things, the quality considerations, unique intellectual property considerations or constraints associated with regulatory requirements.”

Raw materials sourcing

Raw materials generally available from multiple sources, but certain raw materials are single-sourced

90%
Source evidence
“Raw materials essential to our business are generally readily available from multiple sources; however, certain of our raw materials are currently sourced from single suppliers.”

Positioning and strategy

2025 acquisitions

2025 acquisitions totaled $4,960M net of cash, including Inari Medical ($Vascular), Guard Medical (NPWT), Advanced Medical Balloons

95%
Source evidence
“In 2025 we completed various acquisitions for total consideration of $4,960, net of cash acquired.”

Inari acquisition completed February 2025

Inari acquired February 2025, creating new Peripheral Vascular reporting unit with $3,203 goodwill

90%
Source evidence
“With the acquisition of Inari in February 2025 discussed in Note 6 to our Consolidated Financial Statements, we established a new Peripheral Vascular reporting unit consisting of the acquired Inari business.”

Named global competitors by product line

Stryker is one of 4-7 leading global competitors in each product line; key rivals include Zimmer Biomet, Medtronic, J&J MedTech, Smith & Nephew

95%
Source evidence
“We are one of five leading global competitors in Instruments; the other four being Zimmer Biomet Holdings, Inc. (Zimmer), Medtronic plc (Medtronic), Johnson & Johnson MedTech (a subsidiary of Johnson & Johnson) and ConMed Linvatec, Inc.”

Spinal Implants business held for sale and sold to Viscogliosi Brothers, LLC

Spinal Implants disposal group sold to Viscogliosi Brothers, LLC in April 2025; $183 goodwill impairment and $362 estimated loss on disposal

95%
Source evidence
“In April 2025 we completed the sale of the disposal group to the Viscogliosi Brothers, LLC”

Risks, financing, and outlook

Revolving credit facility and commercial paper

New $3,000M revolver (increased by $750) maturing Feb 25, 2030; no revolver or CP borrowings outstanding at Dec 31, 2025

95%
Source evidence
“increasing the aggregate principal amount of the facility by $750 to $3,000 and extending the maturity date to February 25, 2030.”

2025 senior notes issuance and repayments

Issued $3,000M senior notes in Feb 2025 (2027-2035 maturities); repaid $650M 1.150% and $750M 3.375% notes in 2025

95%
Source evidence
“In February 2025 we issued $500 of 4.550% senior unsecured notes due February 10, 2027, $700 of 4.700% senior unsecured notes due February 10, 2028, $800 of 4.850% senior unsecured notes due February 10, 2030 and $1,000 of 5.200% senior unsecured notes due February 10, 2035.”

2025 results summary

2025: net sales +11.2% reported, +10.3% constant currency ex-M&A; net earnings $3,246M; diluted EPS $8.40; adjusted EPS $13.63

95%
Source evidence
“In 2025 we achieved reported net sales growth of 11.2%. Excluding the impact of acquisitions and divestitures, sales grew 10.3% in constant currency.”

Spine reporting unit goodwill impairment charge of $273 (annual test Oct 31, 2024)

$273 goodwill impairment for Spine reporting unit driven by competitive demand decline and higher WACC

95%
Source evidence
“The carrying value of the Spine reporting unit exceeded its fair value and a charge of $273 was recognized in goodwill and other impairments”

EU MDR compliance burden with December 2028 phase-in

Staggered phase-in period for EU MDR compliance through December 2028; significant compliance costs

95%
Source evidence
“changes in regulatory requirements (such as the staggered phase-in period for manufacturers to comply with the European Union Medical Device Regulation (MDR) through December 2028)”

GDPR exposure up to 4% of total revenue

Non-compliance with EU GDPR may result in monetary penalties of up to 4% of total company revenue

96%
Source evidence
“Non-compliance with the GDPR may result in monetary penalties of up to 4% of total company revenue.”

Inflation and cost pass-through limitation

Ongoing inflationary increases in manufacturing costs and operating expenses; unable to pass along all cost increases including tariffs

94%
Source evidence
“We have continued to experience, and may in the future experience, inflationary increases in manufacturing costs and operating expenses, as well as negative impacts from weakening or strengthening exchange rates against the United States Dollar.”

EU litigation regime expansion (Collective Redress & revised Product Liability Directive)

EU Collective Redress Directive and revised Product Liability Directive (fully adopted by December 9, 2026) expose Stryker to additional litigation risks

93%
Source evidence
“The European Product Liability Directive was revised in 2024 and will become fully adopted into each member state's national laws by December 9, 2026.”

Geopolitical conflicts exposure

Exposure to geopolitical conflicts: China-Taiwan tensions, Ukraine war, Middle East war, and related sanctions

93%
Source evidence
“current or potential geopolitical conflicts, such as the tensions between China and Taiwan and the wars in Ukraine and the Middle East, and related sanctions and other developments”

Competitive/technology obsolescence risk incl. AI and robotics

Highly competitive medical device markets; risk that competitors adopt robotics, AI and machine learning faster, rendering products obsolete

93%
Source evidence
“Our existing competitors and new market entrants may respond more quickly to or integrate new or emerging technologies such as robotics, artificial intelligence (AI) and machine learning in their product offerings”

Tariff and macroeconomic risk

2025 US tariffs on imports from dozens of countries expected to increase product costs and impact demand and supply chains

92%
Source evidence
“Tariffs are expected to continue to result in an increase in certain product costs or have adverse impacts on, among other things, demand for our products and supply chains.”

Dependence on healthcare professional relationships

Relies on relationships with respected physicians and medical personnel in hospitals and universities who assist in product research and development

90%
Source evidence
“We rely on these professionals to assist us in the development and improvement of proprietary products.”

Customer/supplier liquidity and credit risk

Experienced loss of sales/profits from delayed payments or insolvency of hospitals and customers facing liquidity issues; may reduce opex or suspend dividends to preserve cash

90%
Source evidence
“we have experienced, and could in the future experience, loss of sales and profits due to delayed payments or insolvency of healthcare professionals, hospitals and other customers and suppliers facing liquidity issues”

Material exposure graph

MedSurg and Neurotechnology
Revenue Exposure

MedSurg and Neurotechnology generated $15,647M (~62%) of 2025 total net sales across Instruments, Endoscopy, Medical, Vascular and Neuro Cranial lines.

Relevance 95·Dependency 62·Confidence 99
Source evidence
“$15,647 $13,518 $12,163”
United States
Revenue Exposure

US accounted for $19,006M of $25,116M 2025 net sales (~76%), growing 12.2% as reported.

Relevance 90·Dependency 76·Confidence 97
Source evidence
“United States $19,006 $16,943 $15,257 12.2%”
Orthopaedics
Revenue Exposure

Orthopaedics generated $9,469M (~38%) of 2025 total net sales across Knees, Hips, Trauma and Extremities, Spinal Implants and Other.

Relevance 90·Dependency 38·Confidence 99
Source evidence
“$9,469 $9,077 $8,335”
Sole-source suppliers and sterilization service providers
Supplier Dependency

Sole-source procurement means supplier failure could halt manufacturing of one or more products; past electronic component shortage caused lost sales.

Relevance 85·Dependency 80·Confidence 95
Source evidence
“If sole-source suppliers or service providers are unable or unwilling to deliver these materials or services as a result of financial difficulties, business disruptions, acquisition by a third party, natural disasters, embargoes, tariffs or otherwise, we may not be able to manufacture or have available one or more products”
Tariffs
Geopolitical Exposure

US tariffs and retaliatory measures could disrupt supply chain, component availability, and cause customers to reduce or delay orders.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“Inflation, high interest rates, interest rate volatility or proposed or enacted tariffs may also cause our customers to reduce or delay orders for our products and services.”
EU Medical Device Regulation (MDR)
Regulatory Exposure

MDR compliance is a significant cost with a staggered phase-in through December 2028; non-compliance risks fines, seizures, recalls, and suspension of manufacturing or sales.

Relevance 80·Dependency 75·Confidence 95
Source evidence
“We incur significant costs to comply with regulations, including the MDR.”
Euro
Currency Exposure

Euro is among the currencies in which ~24% of net sales are denominated; USD strength/weakness drives translation effects.

Relevance 75·Dependency 65·Confidence 96
Source evidence
“approximately 24% of our net sales are denominated in foreign currencies, including the Australian Dollar, British Pound, Canadian Dollar, Euro and Japanese Yen.”
Artificial intelligence / robotics adoption by competitors
Competitive Exposure

Competitors and new entrants may integrate robotics, AI and machine learning more quickly, threatening demand for existing products.

Relevance 75·Dependency 60·Confidence 92
Source evidence
“Our existing competitors and new market entrants may respond more quickly to or integrate new or emerging technologies such as robotics, artificial intelligence (AI) and machine learning in their product offerings”
FDA medical device regulation
Regulatory Exposure

Most products regulated by FDA under the Medical Device Amendments of 1976; many new products require 510(k) notification or pre-market approval with clinical testing.

Relevance 75·Dependency 60·Confidence 92
Source evidence
“many of our new products fall into FDA classifications that require notification submitted as a 510(k) and review by the FDA before we begin marketing them.”
Rejuvenate/ABGII hip stems, LFIT V40 Femoral Heads, Wright legacy hips
Legal Exposure

Ongoing product liability lawsuits over hip implant products create uncertain outcomes and potential significant legal expenses.

Relevance 75·Dependency 50·Confidence 95
Source evidence
“We are currently defendants in a number of product liability matters, including those relating to our Rejuvenate and ABGII Modular-Neck hip stems, LFIT Anatomic CoCr V40 Femoral Heads and the product liability lawsuits and claims relating to Wright Medical Group N.V. (Wright) legacy hip products”
Mako SmartRobotics
Revenue Exposure

Mako robotics is a key Orthopaedics growth platform: >45 countries, >2M cumulative robotic procedures; Mako 4 launched 2025 with first-to-market robotic revision hip application.

Relevance 75·Dependency 45·Confidence 90
Source evidence
“Mako Total Hip with Advanced Primary and Revision represents Stryker's first-to-market, robotically enabled revision hip arthroplasty procedure.”
Stryker Corporation
Competitive Exposure

Spine reporting unit impairment driven by decreased future product demand due to competitive environment.

Relevance 70·Dependency 50·Confidence 90
Source evidence
“The impairment charge for the Spine reporting unit was driven by a decrease in future product demand due to the competitive environment”
Medtronic plc
Competitive Exposure

Medtronic named as a leading global competitor in Instruments and Vascular/Neuro Cranial product lines.

Relevance 70·Dependency 40·Confidence 95
Source evidence
“the other four being Medtronic, Johnson & Johnson MedTech, Terumo Corporation and Penumbra, Inc.”
Zimmer Biomet Holdings, Inc.
Competitive Exposure

Zimmer Biomet named as a leading global competitor in Instruments and in joint replacement, trauma and extremities products and robotics.

Relevance 70·Dependency 40·Confidence 95
Source evidence
“We are one of four leading global competitors for joint replacement and trauma and extremities products and robotics; the other three being Zimmer, Johnson & Johnson MedTech and Smith & Nephew.”
Vascular (Neurovascular + Inari)
Revenue Exposure

Vascular sales grew 50.6% as reported in 2025 to $1,968M, driven by the Inari Medical acquisition (venous thromboembolism products).

Relevance 70·Dependency 40·Confidence 92
Source evidence
“Vascular 1,968 1,307 1,226 50.6 50.0 107.5”
Vascular
Revenue Exposure

Vascular (minimally invasive stroke and venous thromboembolism products) grew rapidly to $1,968M in 2025 from $1,307M in 2024, with US sales more than doubling.

Relevance 70·Dependency 8·Confidence 90
Source evidence
“Vascular 1,968 1,307 1,226”
Tariffs / trade policy
Demand Driver

New 2025 US tariffs and retaliatory measures expected to raise product costs and adversely affect demand and supply chains.

Relevance 65·Dependency 50·Confidence 90
Source evidence
“Tariffs are expected to continue to result in an increase in certain product costs or have adverse impacts on, among other things, demand for our products and supply chains.”
Taxation
Tax Exposure

Multi-jurisdiction tax positions and in-process audits; changes in tax legislation and earnings repatriation could affect effective tax rate.

Relevance 65·Dependency 45·Confidence 90
Source evidence
“certain changes or future events, such as changes in tax legislation, geographic mix of earnings, completion of tax audits or earnings repatriation plans, could have an impact on those estimates and our effective tax rate.”
EU GDPR
Regulatory Exposure

GDPR non-compliance penalties can reach 4% of total company revenue; privacy/AI regulatory compliance costs are increasing.

Relevance 60·Dependency 55·Confidence 95
Source evidence
“Non-compliance with the GDPR may result in monetary penalties of up to 4% of total company revenue.”
Spinal Implants
Revenue Exposure

Spinal Implants sales declined to $185M in 2025 from $707M in 2024, now a de minimis share (~0.7%) of total net sales.

Relevance 55·Dependency 100·Confidence 85
Source evidence
“Spinal Implants 185 707 713”
Certain single-sourced raw materials
Supplier Dependency

Certain raw materials are currently sourced from single suppliers, a supply-chain dependency despite generally multiple sources.

Relevance 55·Dependency 40·Confidence 85
Source evidence
“however, certain of our raw materials are currently sourced from single suppliers.”
AI-assisted virtual care platform technology
Technology Dependency

The Medical product line includes clinical communication and artificial intelligence-assisted virtual care platform technology, an AI-linked product exposure.

Relevance 55·Dependency 20·Confidence 80
Source evidence
“clinical communication and artificial intelligence- assisted virtual care platform technology (Medical)”
Full company information
Latest profile, trading, valuation, and identifier data stored for SYK.
Share price
$339.65
Market cap
$129.30B
Exchange
NYSE
Currency
USD
CEO
Kevin A. Lobo
Employees
56,000
IPO date
17/03/1980
Beta
0.781
Last dividend
$0.00
Day range
$322.68 – $342.27
52-week range
$267.00 – $389.33
1-day performance
9.37%
1-year performance
27.21%
Current drawdown (1Y)
-12.76%
CIK
0000310764
CUSIP
863667101
ISIN
US8636671013
Created
07/12/2025, 14:28:16
Last update
05/11/2026, 10:08:39

Track Stryker Corporation with an AI analyst

See which prediction-market events move SYK, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to SYK from your Railway `news_articles` table.

Here's Why You Should Hold Stryker Stock in Your Portfolio for Now

Zacks Investment Research • STOCK • 12/06/2026, 16:20:36

Stryker Launches TPX HD Power Tool for Complex Orthopedic Procedures

Zacks Investment Research • STOCK • 04/06/2026, 13:25:18

Stryker Launches Pangea Plating System in Europe for Fracture Fixation

Zacks Investment Research • STOCK • 27/05/2026, 14:41:16

Stryker Launches Pangea Plating System and Completes First Case in Europe

Business Wire • STOCK • 26/05/2026, 04:10:00

Stryker Corporation (SYK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 21:20:48

Stryker (NYSE: SYK) Navigates Q1 Earnings Miss Amid Cyber Incident and Strategic Growth

Market Data • Market Data • 02/05/2026, 04:12:59

Stryker Q1 Earnings & Sales Miss Estimates on Cyber Disruption

Zacks Investment Research • STOCK • 01/05/2026, 13:31:27

Stryker Corporation (SYK) Q1 2026 Press Conference Call Transcript

Seeking Alpha • STOCK • 01/05/2026, 02:41:32

Stryker (SYK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Investment Research • STOCK • 30/04/2026, 21:01:06

Stryker (SYK) Q1 Earnings and Revenues Lag Estimates

Zacks Investment Research • STOCK • 30/04/2026, 20:30:15

Stryker to Report Q1 Earnings: What's in Store for the Stock?

Zacks Investment Research • STOCK • 28/04/2026, 11:50:31

Wall Street's Insights Into Key Metrics Ahead of Stryker (SYK) Q1 Earnings

Zacks Investment Research • STOCK • 27/04/2026, 12:15:14